AHA and AHIP Challenge DEA's Telemedicine Prescription Proposal
Washington D.C., Wednesday, 19 March 2025.
AHA and AHIP are concerned about potential access barriers in DEA’s proposal on telemedicine prescriptions, advocating for a streamlined process over burdensome regulations.
Regulatory Framework and Implementation Timeline
The Drug Enforcement Administration’s latest proposal outlines three distinct registration types to replace existing in-person visit requirements for virtual prescribing of controlled substances. The framework requires healthcare providers to obtain state registration for each jurisdiction where they treat patients [1]. A significant aspect of the proposal mandates providers to review prescription drug monitoring programs across all 50 states and territories after a three-year period [1]. The American Hospital Association, in its March 18, 2025 response, has specifically requested a minimum one-year preparatory period following the rule’s finalization to ensure healthcare practitioners can adequately adapt to these changes [1].
Industry Response and Healthcare Access Concerns
While supporting the fundamental concept of special registration replacing in-person requirements, the AHA has raised concerns about the proposal’s efficiency and potential administrative burden [1]. This comes at a time when the healthcare sector is already managing significant operational changes, as evidenced by the American Health Care Association’s membership of over 14,000 facilities working to maintain and improve care delivery standards [2]. The timing is particularly crucial as the healthcare industry continues to adapt to evolving post-acute care needs and specialized care requirements [2].
Recommendations for Streamlined Implementation
The AHA has proposed integrating the registration process within the existing licensure framework to reduce administrative complexity [1]. This recommendation aligns with broader healthcare industry efforts to enhance care delivery efficiency, as demonstrated by recent initiatives in post-acute care and specialized treatment programs [2]. The focus remains on maintaining quality while reducing unnecessary administrative barriers that could impede patient access to necessary medications [GPT].